Past studies analyzing glioma subpopulations has found that various tumorigenic phenotypes and treatment resistance were associated with increased numbers of glioma stem-like cells expressing the CD133 cell surface marker [20, 23]. This evidence concerns the gene PROM1 and central nervous system cancer.